Where Your Money Goes
Every single penny donated goes straight into funding research nurses and helping to fund the Trials Acceleration Program (TAP) across the UK.
The Trials Acceleration Programme (TAP) Network
As of 2022, through Cure Leukaemia’s support, the TAP network have been able to develop 4 brand new trials through direct funding.
The TAP network have also been able to leverage over £6 million in free drugs to be delivered into the NHS, at no cost to them.
There are a total of 12 TAP centres across the UK, and over the past decade, Cure Leukaemia has funded a network of 15 specialist nurses who work across the West Midlands region to administer pioneering drug treatments to leukaemia patients.
4
The need for more trials
“Patients are potentially missing out on life-saving treatment as we simply do not have enough specialist nurses to deliver enough clinical trials. It is deeply frustrating that patients are being turned away and miss out on these important and potentially curative drugs.
The work Cure Leukaemia does is invaluable and has already made a huge impact in the fight against leukaemia and lymphoma. I’d urge people to support the charity as they could make the difference between life and death.”
Ram Malladi Senior Clinical Lecturer/Honorary Consultant Haematologist
Around 12,000 people a year die from blood cancers in Britain, equivalent numbers to those who die from breast cancer. The prospect of survival for many adults with blood cancers is still less than 50%.
There is an urgent need for leukaemia patients to access new, potentially lifesaving drugs so that they can share in the remarkable progress that is being made in so many other cancers.
The battle against leukaemia has already achieved a number of important victories. In 2001, and following significant trials, pioneering drug Glivec was given approval by the FDA in America, and has since transformed the lives of many people with chronic myelogenous leukaemia (CML).